Panitumumab efficacy

Panitumumab was originally approved in September 2006 for the treatment of EGFR-expressing metastatic colorectal cancer (mCRC) with disease progression on or after a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen, based on results from a study showing clinical benefit in patients with metastatic colorectal cancer. Results of a study demonstrating a lack of benefit from the use of panitumumab in patients with NRAS mutations.

Panitumumab occupiesEGFR, thereby preventing the binding of endogenous ligands epidermal growth factor (EGF) or transforming growth factor-alpha. Panitumumab is a pure antagonist. The intracellular processes triggered by EGFR activation are blocked by panitumumab, ultimately leading to increased apoptosis, reduced tumor cell proliferation, and reduced angiogenesis. Therefore, panitumumab prevents tumor growth and the development of metastasis. The study showed that panitumumab was not associated with a survival benefit but improved overall response rates in pretreated patients with metastatic colorectal cancer. Future studies are needed to identify relevant biomarkers in selected patients who are most likely to benefit from panitumumab in refractory mCRC.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.